Your hepatitis C status—active, treated, cured, or never infected—is one of the most important secondary factors underwriters consider alongside your HIV metrics.

How coinfection affects your underwriting profile

Each health condition an underwriter evaluates adds to the overall risk profile. HIV and hepatitis C are each individually underwritten, and when both are present, the combined risk profile is more complex than either alone.

HCV affects the liver, causing inflammation that can lead to fibrosis, cirrhosis, and liver cancer over time. People with HIV-HCV coinfection historically progressed to liver fibrosis faster than people with HCV alone. This accelerated progression made HCV coinfection a significant mortality concern from an underwriting perspective.

Modern direct-acting antiviral (DAA) treatment has fundamentally changed this picture. HCV is now curable in more than 95 percent of cases with an 8 to 12 week course of DAA therapy. People who achieve a sustained virologic response (SVR)—undetectable HCV RNA 12 weeks after completing treatment—are considered cured. Liver fibrosis can also improve after cure in many people. This changes the underwriting calculation significantly.

Active vs treated vs resolved hepatitis C

Where you are in the HCV journey matters enormously for life insurance underwriting:

The most important distinction is between active/untreated HCV and cured (SVR) HCV. If you have active HCV and have not been treated, pursuing DAA treatment before applying for life insurance is one of the most impactful steps you can take to improve your underwriting position.

What carriers look for when both conditions are present

For applicants with both HIV and HCV, underwriters evaluate the combined health picture. The HIV metrics remain central:

• HIV viral load: Must be undetectable. This is the primary gate even when HCV is also present.
• CD4 count: Must be above carrier thresholds. The standard requirements apply.
• HCV status: Active vs. treated vs. cured, and if cured, how long ago and what the SVR documentation shows.
• Liver function: Liver enzyme levels (ALT, AST) and any evidence of fibrosis or cirrhosis. Carriers evaluate liver health separately from HCV status.
• Liver disease severity: Evidence of significant fibrosis, cirrhosis, or portal hypertension dramatically limits options regardless of HCV treatment status.
• Duration since SVR: More time since HCV cure is generally more favorable. Many carriers want to see at least 12 to 24 months post-SVR before fully integrating the improved outlook into underwriting.

Coverage options with coinfection

Coverage availability depends significantly on HCV status at the time of application:

With active, untreated HCV: Traditional life insurance coverage is very limited. Most carriers will not approve an application with both active HIV and untreated active HCV. The risk profile is too elevated. Guaranteed issue life insurance remains available, with its characteristic limitations on face amount and graded benefit period. Employer group life insurance, which does not involve individual health underwriting, may be the other primary option.

With HCV cured (SVR): Options expand meaningfully. A subset of carriers that accept HIV-positive applicants will also consider applications where HCV has been successfully treated. The same HIV metrics apply (undetectable viral load, adequate CD4 count), and additional documentation of SVR and current liver function will be requested. Face amounts may be more limited than for HIV-only applicants at similar carriers, but traditional term or whole life coverage is a realistic goal.

Working with a specialist broker is even more important with coinfection than with HIV alone. The field of carriers willing to consider HIV-HCV coinfection is narrower, and navigating the informal inquiry process without creating MIB records from incorrect applications requires specific knowledge of current carrier guidelines.

How DAA treatment changes the picture

Direct-acting antiviral (DAA) drugs, introduced broadly from around 2014, represent one of the most significant advances in infectious disease treatment of the past decade. Drugs like sofosbuvir, ledipasvir, velpatasvir, and others have transformed HCV treatment from a difficult, partially effective year-long interferon regimen to an 8 to 12 week oral course with cure rates above 95 percent.

For life insurance purposes, DAA treatment and SVR matter because:

First, HCV cure removes the ongoing liver damage from active HCV infection. The liver can recover to varying degrees after cure, with studies showing fibrosis regression in many patients. Underwriters recognize that a cured HCV infection is fundamentally different from an active infection.

Second, DAA treatment is accessible. HCV is no longer a condition that people have to live with indefinitely because treatment was difficult or expensive. The availability of effective, well-tolerated treatment means that active HCV is increasingly a choice to have addressed rather than an uncontrollable condition. Underwriters factor this in—both in recognizing cured HCV as improved and in viewing untreated HCV with more concern than before effective treatment existed.

If you have HCV and have not yet been treated, this is a strong reason to pursue DAA treatment: for your health, and for your life insurance options.

Applying after HCV cure

If you have achieved SVR from HCV treatment, here is how to approach a life insurance application:

• Gather documentation of SVR: Your HCV specialist’s records showing undetectable HCV RNA at the 12-week post-treatment confirmation (SVR12). This is the clinical standard for cure and what carriers will look for.
• Get current liver function tests: A current metabolic panel showing ALT, AST, and other liver function markers tells the underwriter how your liver has recovered post-cure.
• Allow time to pass after cure: Many carriers want to see 12 to 24 months post-SVR before fully updating their underwriting assessment. Applying too soon after HCV cure may not capture the full benefit of improved liver health in the underwriting decision.
• Work with a specialist broker: The carrier selection step is especially important here. Not all HIV-friendly carriers are also HCV-coinfection-friendly. A broker who works with coinfected clients knows which carriers to approach.

Common questions about HIV-HCV coinfection and insurance

Written and reviewed by Phillip Chin

Licensed Insurance Broker · NPN #8895251. Phillip is an independent broker who specializes in life insurance for people living with HIV, comparing the carriers that actually approve HIV-positive applicants.

Educational information from LifeInsuranceHIV.com, an independent brokerage. All coverage is subject to carrier underwriting and approval; eligibility, rates, and availability vary by carrier, state, and individual circumstances. Figures are estimates, not guarantees or offers of coverage.